Anti-Human MCP-3 (Clone 36320)
Anti-Human MCP-3 (Clone 36320)
Product No.: M153
- -
- -
Clone 36320 Target MCP-3 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names CCL7, SCYA6, SCYA7, Small Inducible Cytokine A7, CCL7, NC28, Chemokine (C-C Motif) Ligand 7, FIC, MARC, MGC138463, MGC138465 Isotype IgG1 Applications CyTOF® , ELISA Cap , FC , N , WB |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Host Species Mouse Immunogen E. coli-Derived Recombinant Human CCL7 (Accession # Q7Z7Q8) Endotoxin Level <0.1 EU/µg as determined by the LAL method Formulation This monoclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.4 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present. Storage and Handling The lyophilized antibody can be stored desiccated at -20°C to -70°C for up to twelve months. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid repeated freeze thaw cycles. No detectable loss of activity was observed after six months. Country of Origin USA Shipping Next Day Ambient RRIDAB_2831357 Applications and Recommended Usage? Quality Tested by Leinco ELISA Sandwich: This antibody is useful as the capture antibody in a sandwich ELISA. The suggested coating concentration is 2-8 µg/ml. A suitable detection antibody is PN:M125 at a concentration of approximately 0.1-0.4 µg/ml. A suggested standard for this assay is PN:M158. Flow Cytometry: It is recommended to use the indirect method for signal enhancement when enumerating cells expressing MCP-3. A suggested method would be to stain cells expressing MCP-3 with 0.25 µg x 106 cells in a total staining volume of ≤200 µl followed by PN:M1189. Western Blotting: To detect Human MCP-3 this monoclonal antibody can be used at a concentration of 1 - 2 µg/ml. This monoclonal antibody should be used in conjunction with compatible second-step reagents such as PN:M114 and a chromogenic substrate such as PN:T343. The detection limit for Human MCP-3 is 5 and 20 ng/lane under either reducing or non-reducing conditions. The sensitivity of detection may increase up to 50 fold when a chemiluminescent substrate is used. A suitable Western blotting control is PN:M158. Additional Applications Reported In Literature ? Neutralization: This antibody is useful for neutralization of Human MCP-3 bioactivity. The antibody dose required to neutralize 50% (ND50) of the biological activity of Human MCP-3 (at 1.0 ng/ml) is 1.5 - 4.5 µg/ml. CyTOF-ready: Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation. Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Mouse Anti-Human Monocyte Chemotactic Protein-3 (MCP-3) (Clone 36320) recognizes an epitope on Human MCP-3. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype. Background Monocyte chemotactic protein-3 (MCP3) is a non-glycosylated polypeptide belonging to the the CC-Chemokines family that attracts monocytes and eosinophils, augments monocyte anti-tumor activity, and induces the release of gelatinase B. It also regulates protease secretion by macrophages. MCP3 can bind heparin.1 MCP-3 is one of the most pluripotent chemokines since it activates all types of leukocytes. MCP-3 may affect HIV-1 infection via inhibiting the binding of HIV envelope to CCR5.2 MCP-3 has also been implicated in Multiple Sclerosis, allergic reactions and viral infections.3,4,5 PubMed References & Citations1. Van Damme, J. et al. (1993) Biochem. Biophys. Res. Commun. 191: 535 2. Parmentier, M. et al. (1999) Blood 94: 1899 3. Brosnan, CF. et al. (1998) J Neuroimmunol. 86: 20 4. Reddigari, SR. et al. (1995) Exp. Dermatol. 4: 260 5. Matikainen, S. et al. (2001) Cytokine Growth Factor Rev. 12: 171 Technical ProtocolsCertificate of Analysis |
Related Products
- -
- -
Prod No. | Description |
---|---|
M144 | |
M158 | |
M175 | |
M134 | |
M126 | |
M125 |
Formats Available
